158 related articles for article (PubMed ID: 16419164)
1. Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography.
Zheng RQ; Zhang B; Kudo M; Sakaguchi Y
World J Gastroenterol; 2005 Oct; 11(40):6348-53. PubMed ID: 16419164
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronic liver disease: a preliminary study by contrast-enhanced coded phase-inversion harmonic sonography.
Sakaguchi Y; Kudo M; Zheng RQ; Chung H; Minami Y; Ogawa C; Kitano M; Kawasaki T; Maekawa K
J Med Ultrason (2001); 2005 Dec; 32(4):197-204. PubMed ID: 27277489
[TBL] [Abstract][Full Text] [Related]
3. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles.
Shunichi S; Hiroko I; Fuminori M; Waki H
Ultrasound Med Biol; 2009 Nov; 35(11):1819-27. PubMed ID: 19713032
[TBL] [Abstract][Full Text] [Related]
4. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C.
Lim AK; Taylor-Robinson SD; Patel N; Eckersley RJ; Goldin RD; Hamilton G; Foster GR; Thomas HC; Cosgrove DO; Blomley MJ
Gut; 2005 Jan; 54(1):128-33. PubMed ID: 15591518
[TBL] [Abstract][Full Text] [Related]
5. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography.
Ishibashi H; Maruyama H; Takahashi M; Fujiwara K; Imazeki F; Yokosuka O
Liver Int; 2010 Oct; 30(9):1355-63. PubMed ID: 20704652
[TBL] [Abstract][Full Text] [Related]
6. Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio.
Wen YL; Kudo M; Zheng RQ; Ding H; Zhou P; Minami Y; Chung H; Kitano M; Kawasaki T; Maekawa K
AJR Am J Roentgenol; 2004 Apr; 182(4):1019-26. PubMed ID: 15039180
[TBL] [Abstract][Full Text] [Related]
7. Obliteration of gastric varices improves the arrival time of ultrasound contrast agents in hepatic artery and vein.
Furuichi Y; Moriyasu F; Sugimoto K; Taira J; Sano T; Miyata Y; Sofuni A; Itoi T; Nakamura I; Imai Y
J Gastroenterol Hepatol; 2013 Sep; 28(9):1526-31. PubMed ID: 23611144
[TBL] [Abstract][Full Text] [Related]
8. Effect of Levovist on splanchnic hemodynamics in cirrhotic patients.
Gaiani S; Serra C; Piscaglia F; Celli N; Rasciti L; Miglioli M; Bolondi L
Ultrasound Med Biol; 2003 May; 29(5):643-8. PubMed ID: 12754063
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent.
Albrecht T; Blomley MJ; Cosgrove DO; Taylor-Robinson SD; Jayaram V; Eckersley R; Urbank A; Butler-Barnes J; Patel N
Lancet; 1999 May; 353(9164):1579-83. PubMed ID: 10334257
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Vein Arrival Time for Diagnosis of Liver Cirrhosis: A 10-Year Single-Center Experience With Contrast-Enhanced Sonography.
Abbattista T; Ridolfi F; Consalvo GT; Brunelli E
J Ultrasound Med; 2016 Oct; 35(10):2121-8. PubMed ID: 27503751
[TBL] [Abstract][Full Text] [Related]
11. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis.
Sugimoto H; Kaneko T; Hirota M; Tezel E; Nakao A
J Hepatol; 2002 Nov; 37(5):578-83. PubMed ID: 12399222
[TBL] [Abstract][Full Text] [Related]
12. Microbubble disappearance-time is the appropriate timing for liver-specific imaging after injection of Levovist.
Maruyama H; Matsutani S; Okugawa H; Kobayashi S; Yoshizumi H; Ebara M; Saisho H
Ultrasound Med Biol; 2006 Dec; 32(12):1809-15. PubMed ID: 17169692
[TBL] [Abstract][Full Text] [Related]
13. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver.
Kaneko T; Teshigawara O; Sugimoto H; Hirota M; Inoue S; Takeda S; Nakao A
Liver Int; 2005 Apr; 25(2):288-93. PubMed ID: 15780052
[TBL] [Abstract][Full Text] [Related]
14. Characterization of focal hepatic lesions in cirrhotic patients by Pulse Inversion Harmonic Imaging US contrast specific technique with Levovist.
Quaia E; Forgács B; Calderan L; Bertolotto M; Pozzi Mucelli R
Radiol Med; 2002 Oct; 104(4):285-94. PubMed ID: 12569309
[TBL] [Abstract][Full Text] [Related]
15. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease.
Pedersen JF; Larsen VA; Bytzer P; Madsen LG; Hamberg O
Acta Radiol; 2005 Oct; 46(6):557-60. PubMed ID: 16334835
[TBL] [Abstract][Full Text] [Related]
16. [Variants of the hepatic artery: detection with color--coded sonography pre and post levovist injection].
Strunk H; von Falkenhausen M; Hofer U; Remig J; König R; Wilhelm K; Textor J
Ultraschall Med; 1999 Feb; 20(1):26-30. PubMed ID: 10226344
[TBL] [Abstract][Full Text] [Related]
17. A study of the intrahepatic vasculature in the human fetus, in the normal adult and in adults with portal cirrhosis.
Hidayet MA; Wahid HA; Hidayet AM; Hidayet NM
Surg Gynecol Obstet; 1977 Sep; 145(3):378-88. PubMed ID: 888058
[No Abstract] [Full Text] [Related]
18. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography.
Li N; Ding H; Fan P; Lin X; Xu C; Wang W; Xu Z; Wang J
Ultrasound Med Biol; 2010 Jul; 36(7):1066-75. PubMed ID: 20620694
[TBL] [Abstract][Full Text] [Related]
19. Contrast-enhanced ultrasonography using Sonazoid to evaluate changes in hepatic hemodynamics in acute liver injury.
Miyazaki M; Kato M; Tanaka M; Tanaka K; Takao S; Kohjima M; Ito T; Enjoji M; Nakamuta M; Kotoh K; Takayanagi R
J Gastroenterol Hepatol; 2011 Dec; 26(12):1749-56. PubMed ID: 21615794
[TBL] [Abstract][Full Text] [Related]
20. Hepatic vein transit time of second-generation ultrasound contrast agent: new tool in the assessment of portal hypertension.
Luisa S; Vitale G; Sorbo AR; Maurizio P; Lodovico RG
J Ultrasound; 2017 Mar; 20(1):43-52. PubMed ID: 28298943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
